FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3085555243> ?p ?o ?g. }

• W3085555243 endingPage "77" @default.
• W3085555243 startingPage "70" @default.
• W3085555243 abstract "Flumatinib has been shown to be a more potent inhibitor of BCR-ABL1 tyrosine kinase than imatinib. We evaluated the efficacy and safety of flumatinib versus imatinib, for first-line treatment of chronic phase Philadelphia chromosome-positive chronic myeloid leukemia (CML-CP).In this study, 394 patients were randomized 1:1 to flumatinib 600 mg once daily (n = 196) or imatinib 400 mg once daily (n = 198) groups.The rate of major molecular response (MMR) at 6 months (primary endpoint) was significantly higher with flumatinib than with imatinib (33.7% vs. 18.3%; P = 0.0006), as was the rate of MMR at 12 months (52.6% vs. 39.6%; P = 0.0102). At 3 months, the rate of early molecular response (EMR) was significantly higher in patients receiving flumatinib than in those receiving imatinib (82.1% vs. 53.3%; P < 0.0001). Compared with patients receiving imatinib, more patients receiving flumatinib achieved molecular remission 4 (MR4) at 6, 9, and 12 months (8.7% vs. 3.6%, P = 0.0358; 16.8% vs. 5.1%, P = 0.0002; and 23.0% vs. 11.7%, P = 0.0034, respectively). No patients had progression to accelerated phase or blast crisis in the flumatinib arm versus 4 patients in the imatinib arm by 12 months. Adverse events of edema, pain in extremities, rash, neutropenia, anemia, and hypophosphatemia were more frequent in imatinib arm, whereas diarrhea and alanine transaminase elevation were more frequent in flumatinib arm.Patients receiving flumatinib achieved significantly higher rates of responses, and faster and deeper responses compared with those receiving imatinib, indicating that flumatinib can be an effective first-line treatment for CML-CP. This trial was registered at www.clinicaltrials.gov as NCT02204644.See related commentary by Müller, p. 3." @default.
• W3085555243 created "2020-09-21" @default.
• W3085555243 creator A5000239300 @default.
• W3085555243 creator A5005994170 @default.
• W3085555243 creator A5010680257 @default.
• W3085555243 creator A5016406818 @default.
• W3085555243 creator A5016890292 @default.
• W3085555243 creator A5021687717 @default.
• W3085555243 creator A5027007747 @default.
• W3085555243 creator A5027908353 @default.
• W3085555243 creator A5028939393 @default.
• W3085555243 creator A5038805449 @default.
• W3085555243 creator A5040795581 @default.
• W3085555243 creator A5043267366 @default.
• W3085555243 creator A5048883481 @default.
• W3085555243 creator A5051993838 @default.
• W3085555243 creator A5063481044 @default.
• W3085555243 creator A5066716873 @default.
• W3085555243 creator A5071443000 @default.
• W3085555243 creator A5072453373 @default.
• W3085555243 creator A5072458792 @default.
• W3085555243 creator A5074069807 @default.
• W3085555243 creator A5076024438 @default.
• W3085555243 creator A5079289633 @default.
• W3085555243 creator A5080969569 @default.
• W3085555243 creator A5085018290 @default.
• W3085555243 creator A5086214965 @default.
• W3085555243 creator A5087592842 @default.
• W3085555243 creator A5090610771 @default.
• W3085555243 date "2021-01-01" @default.
• W3085555243 modified "2023-10-09" @default.
• W3085555243 title "Flumatinib versus Imatinib for Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia: A Phase III, Randomized, Open-label, Multi-center FESTnd Study" @default.
• W3085555243 cites W1210836019 @default.
• W3085555243 cites W1816965539 @default.
• W3085555243 cites W1970263384 @default.
• W3085555243 cites W1981567666 @default.
• W3085555243 cites W1981809014 @default.
• W3085555243 cites W1997730029 @default.
• W3085555243 cites W2013450609 @default.
• W3085555243 cites W2030615871 @default.
• W3085555243 cites W2052923507 @default.
• W3085555243 cites W2054774757 @default.
• W3085555243 cites W2058216377 @default.
• W3085555243 cites W2065974896 @default.
• W3085555243 cites W2068645465 @default.
• W3085555243 cites W2076668534 @default.
• W3085555243 cites W2084397515 @default.
• W3085555243 cites W2084734126 @default.
• W3085555243 cites W2085342571 @default.
• W3085555243 cites W2097799776 @default.
• W3085555243 cites W2107268345 @default.
• W3085555243 cites W2112810605 @default.
• W3085555243 cites W2124097332 @default.
• W3085555243 cites W2143939343 @default.
• W3085555243 cites W2145835848 @default.
• W3085555243 cites W2148743957 @default.
• W3085555243 cites W2151486690 @default.
• W3085555243 cites W2166654361 @default.
• W3085555243 cites W2167325977 @default.
• W3085555243 cites W2260921597 @default.
• W3085555243 cites W2265596863 @default.
• W3085555243 cites W2313607879 @default.
• W3085555243 cites W2397234997 @default.
• W3085555243 cites W2473480037 @default.
• W3085555243 cites W2520429294 @default.
• W3085555243 cites W2551058677 @default.
• W3085555243 cites W2587781815 @default.
• W3085555243 cites W2592060299 @default.
• W3085555243 cites W2750206713 @default.
• W3085555243 cites W2759146932 @default.
• W3085555243 cites W2766187515 @default.
• W3085555243 cites W2900357627 @default.
• W3085555243 cites W2906487595 @default.
• W3085555243 cites W2938772811 @default.
• W3085555243 cites W2981324571 @default.
• W3085555243 doi "https://doi.org/10.1158/1078-0432.ccr-20-1600" @default.
• W3085555243 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32928796" @default.
• W3085555243 hasPublicationYear "2021" @default.
• W3085555243 type Work @default.
• W3085555243 sameAs 3085555243 @default.
• W3085555243 citedByCount "22" @default.
• W3085555243 countsByYear W30855552432020 @default.
• W3085555243 countsByYear W30855552432021 @default.
• W3085555243 countsByYear W30855552432022 @default.
• W3085555243 countsByYear W30855552432023 @default.
• W3085555243 crossrefType "journal-article" @default.
• W3085555243 hasAuthorship W3085555243A5000239300 @default.
• W3085555243 hasAuthorship W3085555243A5005994170 @default.
• W3085555243 hasAuthorship W3085555243A5010680257 @default.
• W3085555243 hasAuthorship W3085555243A5016406818 @default.
• W3085555243 hasAuthorship W3085555243A5016890292 @default.
• W3085555243 hasAuthorship W3085555243A5021687717 @default.
• W3085555243 hasAuthorship W3085555243A5027007747 @default.
• W3085555243 hasAuthorship W3085555243A5027908353 @default.
• W3085555243 hasAuthorship W3085555243A5028939393 @default.
• W3085555243 hasAuthorship W3085555243A5038805449 @default.
• W3085555243 hasAuthorship W3085555243A5040795581 @default.
• W3085555243 hasAuthorship W3085555243A5043267366 @default.

• next